HoloLens
At the beginning of the pandemic, it was announced that Microsoft HoloLens Mixed Reality headsets were to be used by frontline medical staff in the fight against COVID-19. The technology offered the possibility of remote care in the midst of a highly contagious and deadly virus and enabled clinicians at Imperial College Healthcare NHS trust to visit patients in high-risk wards in full PPE and a HoloLens. This system then enabled clinicians to feed live footage to colleagues in a low-risk area through the Dynamics 365 Remote Assist app.
A year later, the headset technology is still showing considerable value by reducing the amount of time staff are spending in high-risk areas and significantly reducing personal protective equipment (PPE) usage, as only the doctor wearing the headset is required to dress in PPE. Imperial College Healthcare NHS trust has said that using HoloLens has led to a fall in the amount of time staff are spending in high-risk areas of up to 83%. It ha
June 5, 2021
LONDON: A majority of major hospital trusts in England are continuing to average no Covid-19 admissions, though a handful of trusts in virus hotspots are showing a small rise in numbers, new analysis shows.
It comes as health experts warn that the Covid-19 variant that originated in India, also known as the Delta variant, may lead to an increased risk of hospital admission. Some 278 people with the Indian variant attended A&Es in England in the past week, resulting in 94 people being admitted to hospital overnight, according to Public Health England (PHE).
This compares with 201 A&E attendances in the previous week, with 43 admissions. However the majority of admissions continue to be people who have not been vaccinated, PHE said.
Date Time
Blood clot-busting nanocapsules could reduce existing treatment’s side effects
Imperial researchers have designed drug delivery nanocapsules that could reduce the side effects of a major blood clot dissolving drug.
Tested on human blood in the lab, the selective nanocapsules could reduce the side effects of a major blood clot dissolving drug, which include bleeding on the brain. If confirmed with animal tests, the nanocapsules could also make the drug more effective at lower doses.
We have wrapped (the drug) in a package that extends this therapeutic window and minimises the required dose. Our results are exciting but animal and clinical studies are required for validation. Dr Rongjun Chen Department of Chemical Engineering